Find and Pitch Jounalists, Get Your Story Covered

Tags: Addiction health addiction | drug development | opioids | Pharmaceuticals | public health | STAT Breakthrough Summit art history drug addiction

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 1 day ago STAT+: Pharmalittle: We’re reading about Trump and tariff worries, PBM rules in New York, and more - 3 days ago STAT+: Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds - 5 days ago STAT+: Up and down the ladder: The latest comings and goings - 16 days ago STAT+: Up and down the ladder: The latest comings and goings - 23 days ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 23 days ago STAT+: To mitigate drug shortages, a new study suggests looking at Canada - 24 days ago STAT+: Up and down the ladder: The latest comings and goings - 30 days ago STAT+: Sales from controversial drug discount program rose to $63 billion last year - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more - 9 months ago STAT+: Oregon suspends a portion of its drug transparency law found to be unconstitutional - 9 months ago STAT+: Pharmalittle: We’re reading about slow uptake of an Alzheimer’s drug, an opioid lawsuit, and more - 9 months ago STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers - 11 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 11 months ago
2	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 3 months ago Listen: Live! From the STAT Breakthrough Summit East - 8 months ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago More evidence on GLP-1s and opioid addiction - about 1 month ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 3 months ago
4	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights - about 1 month ago Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target - 3 months ago STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal - 3 months ago Listen: Live! From the STAT Breakthrough Summit East - 8 months ago STAT Virtual Event \| Cancer’s Breakthrough Engine - 11 months ago
5	Theresa Gaffney STAT News Audio producer, health reporter. Boston audio productionhealth reporting	Morning Rounds: Highlights from the STAT Summit - about 1 month ago
6	Emily Olsen Healthcare Dive Reporter at Healthcare Dive. Loyola, Medill alum. Chicago, Illinois HealthcareNews	Lawmakers urge Biden administration to extend telehealth prescribing flexibilities for opioid use disorder - about 2 months ago
7	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	STAT+: Rick Doblin, ‘unleashed,’ blasts FDA over Lykos drug rejection and turns to global push for MDMA therapy - 3 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 6 months ago
8	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Conference Recap: McKesson ideaShare - 3 months ago
9	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors - 4 months ago
10	Nick Paul Taylor MedTech Dive Top 5 Mario Kart Player. Gaming	FDA finalizes guidance on studying opioid use disorder treatments - 5 months ago

Journalists covering addiction | drug development | opioids | Pharmaceuticals | public health | STAT Breakthrough Summit